CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding

Rhea-AI Filing Summary

CytomX Therapeutics Chief Financial Officer Christopher Ogden reported an open-market sale of 1,624 shares of common stock on June 15, 2026 at an average price of $3.05 per share. According to the disclosure, the shares were sold solely to satisfy tax and other government withholding obligations arising from the vesting of restricted stock units, so the transaction reflects a tax-related event rather than a discretionary portfolio move.

After this sale, Ogden holds a total of 295,324 shares of CytomX Therapeutics common stock, including 167,249 restricted stock units that will convert into shares as they vest over time. The sale represents a small portion of his overall direct equity position, indicating that he retains substantial exposure to the company’s stock following this routine tax-withholding transaction.

Insider Trade Summary

Net Seller: 1,624 shares

Net Sell 1 txn

Insider Ogden Christopher

Role Chief Financial Officer

Sold 1,624 shs ($5K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,624	$3.05	$5K

Holdings After Transaction: Common Stock — 295,324 shares (Direct)

Footnotes (2)

1. F1. The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
2. F2. Includes 167,249 RSUs.

Key Figures

Shares sold: 1,624 shares Sale price: $3.05 per share Shares held after transaction: 295,324 shares +1 more

4 metrics

Shares sold 1,624 shares Open-market sale on June 15, 2026

Sale price $3.05 per share Average price for the June 15, 2026 sale

Shares held after transaction 295,324 shares Total direct holdings following the sale

RSUs included in holdings 167,249 RSUs Restricted stock units included in post-transaction total

Key Terms

restricted stock units, open-market sale, withholding obligations

3 terms

restricted stock units financial

"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

withholding obligations financial

"sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units"

FAQ

What insider transaction did CytomX (CTMX) disclose for CFO Christopher Ogden?

CytomX disclosed that CFO Christopher Ogden sold 1,624 shares of common stock on June 15, 2026 at $3.05 per share. The filing states this sale was made solely to cover tax and other government withholding obligations from restricted stock unit vesting.

Was the CytomX (CTMX) CFO’s share sale a discretionary trade or tax-related?

The sale was described as tax-related, not discretionary. Footnotes explain the 1,624 shares were sold solely to satisfy tax or other government withholding obligations triggered by vesting restricted stock units, a common administrative step when equity awards convert into shares.

How many CytomX (CTMX) shares does CFO Christopher Ogden hold after the transaction?

After the June 15, 2026 sale, CFO Christopher Ogden holds 295,324 shares of CytomX common stock. This total includes 167,249 restricted stock units, which are promises of future shares that will settle into stock as vesting conditions are met over time.

What price did the CytomX (CTMX) CFO receive for the shares sold?

The CFO’s tax-related sale was executed at an average price of $3.05 per share. This applied to 1,624 shares of CytomX common stock sold on June 15, 2026, generating cash used to cover government withholding obligations tied to equity award vesting.

How significant is the CytomX (CTMX) CFO’s share sale relative to his total holdings?

The 1,624 shares sold represent a small fraction of the CFO’s 295,324-share position. Because the filing states the sale was solely for tax and withholding obligations, it appears as a routine administrative transaction rather than a large change in his investment exposure.

What are restricted stock units (RSUs) mentioned in the CytomX (CTMX) Form 4?

Restricted stock units are share-based awards that convert into common stock as vesting conditions are met. The filing notes that the CFO’s post-transaction holdings include 167,249 RSUs, which will deliver CytomX shares over time, subject to continued service or other vesting requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/17/2026 - 06:39 PM Accepted by SEC EDGAR 06/17/2026 - 06:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ogden Christopher

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., SUITE 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		S(1)		1,624	D	$3.05	295,324(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

2. Includes 167,249 RSUs.

	/s/ Christopher Ogden	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)